Objective: In this study, a serological survey was conducted in unvaccinated sheep and goat populations at Pyawbwe and Meikhtila townships of Mandalay region in Myanmar to determine the seroprevalence and associated risk factors of foot and mouth disease (FMD). Materials and methods: A total of 110 sheep and 107 goat sera samples were randomly collected from Pyawbwe. Similarly, 108 sheep and 109 goat sera were collected from Meikhtila. All samples were tested for the presence of nonstructural protein (NSP) specific antibodies to FMD virus (FMDV) by Ceditest FMDV-NSP Enzyme-lined Immunosorbent Assay (ELISA), and were confirmed by Liquid Phase Blocking ELISA (LPB ELISA) . Results: Overall seroprevalence was 42.4%(n=184/434) by Ceditest-NSP ELISA, and 46.8%(n=203/434) by LPB ELISA against FMDV serotype O. The presence of antibodies against FMDV serotype O was higher (P<0.01) as compared to those of serotype A and Asia-1. The seroprevalence in Meikhtila (49.77%) was higher (P<0.01) than that of Pyawbwe (35.2%). The seropositivity in sheep and goats that were in-contact (77.19%) with infected cattle and pigs was higher (P<0.01) as compared to those in-contact with non-infected animals (37.14%). Similarly, the seropositivity in sheep and goats from high animal trade areas (49.4%) was higher (P<0.05) than that of those from low animal trade areas (37.97%). Conclusion: Rearing of sheep and goats in-contact with FMDV-infected cattle and pigs, and high animal trading areas are the major associated risk factors for FMDV infection for sheep and goats in the study areas in Myanmar.

Staphylococcus aureus is the most important human and animal pathogen responsible for a wide spectrum of morbidity and acute clinical infections, in addition to tenacious chronic forms of diseases. The pathogen sophisticated virulence, and its abilities to abate or elude the host immune responses by the myriad of processes makes it the most dreaded organisms, both in the communities, hospital setups and the dairy industries worldwide. S. aureus vaccines have revealed a significant challenge because of plentiful virulence physiognomies. For these reasons, numerous protein particles and several potent transporters of these proteins called adjuvants were proposed as ideal vaccines contrivances for the prevention of Staphylococcus aureus infections. Furthermore, for the formulation of these vaccine contraptions nascent technologies which include the Bioinformatics, Proteomics, Metagenomics, Metabolomics, Transcriptomics and Nanotechnology and its ability in the deliverance of vaccines in research are similarly advocated, an intact procedure employed for the evaluation of the vast proteins and genes that were disclosed by a microorganism is currently available. Likewise, existing are marvellous expectation in these burgeoning expertise in understanding the microbial and host affiliations. In view of this, the blossoming facts may perhaps tremendously assure to the headway of immunogenic vaccines as anti-Staphylococcus aureus contagions in both hominids and animals. This periodical highlights and explicates on the up-to-date eminence of mucosal and systemic immune responses by the application of Transcriptomics, Metabolomics, Metagenomics, Proteomics and Nanotechnology techniques for their prominence in the evaluation of refined proteins for use as systemic and mucosal immunogenic vaccines for forefending of Staphylococcus aureus contagions in goats, sheep and cattle.

The development and utilization of nano-antibiotics is currently gaining attention as a possible solution to antibiotic resistance. The aim of this study was therefore to determine the pharmacokinetics of free oxytetracycline (OTC) and oxytetracycline loaded cockle shell calcium carbonate-based nanoparticle (OTC-CNP) after a single dose of intraperitoneal (IP) administration in BALB/c mice. A total of 100 female BALB/c mice divided into two groups of equal number (n = 50) were administered with 10 mg/kg OTC and OTC-CNP, respectively. Blood samples were collected before and post-administration from both groups at time 0, 5, 10, 15, and 30 min and 1, 2, 6, 24, and 48 h, and OTC plasma concentration was quantified using a validated HPLC-UV method. The pharmacokinetic parameters were analyzed using a non-compartment model. The C max values of OTC in OTC-CNP and free OTC treated group were 64.99 and 23.53 µg/ml, respectively. OTC was detected up to 24 h in the OTC-CNP group as against 1 h in the free OTC group following intraperitoneal administration. In the OTC-CNP group, the plasma elimination rate of OTC was slower while the half-life, the area under the curve, and the volume of the distribution were increased. In conclusion, the pharmacokinetic profile of OTC in the OTC-CNP group differs significantly from that of free OTC. However, further studies are necessary to determine the antibacterial efficacy of OTC-CNP for the treatment of bacterial diseases.